(Q38286163)

1 September 2017

1 reference

title

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (English)

1 reference

1 September 2017

metastatic breast cancer

1 reference

1 reference

1 reference

2

Tsutomu Takashima

1 reference

1 September 2017

Hidemi Kawajiri

1

1 reference

1 September 2017

Shinichiro Kashiwagi

3

1 reference

1 September 2017

Satoru Noda

4

1 reference

1 September 2017

Naoyoshi Onoda

5

1 reference

1 September 2017

Kosei Hirakawa

6

1 reference

1 September 2017

language of work or name

1 reference

12 December 2014

1 reference

Expert Review of Anticancer Therapy

1 September 2017

1 reference

1 September 2017

15

1 reference

1 September 2017

1

1 reference

1 September 2017

17-26

1 reference

Trastuzumab: triumphs and tribulations

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

1st International consensus guidelines for advanced breast cancer (ABC 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Pertuzumab in breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Clinical pharmacokinetics of docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

P95 HER2 fragments and breast cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

A systematic review of dual targeting in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Recurrent glioblastoma: not only surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.992418

10.1586/14737140.2015.992418

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference